ACKNOWLEDGMENT OF GOVERNMENT RIGHTS

This invention was made with Government support under grant number DK43805-01A2 awarded by the National Institutes of Health. The Government has certain rights in this invention.--

IN THE CLAIMS:

Please cancel claim 1 and add new claims 23-49 as follows.

23. A method of treating an individual suspected of suffering from colorectal cancer comprising the step of administering to said individual a therapeutically effective amount of a pharmaceutical composition that comprises:

a) an ST receptor ligand;

b) an active agent, wherein the active agent causes cell death; and

c) a pharmaceutically acceptable carrier or diluent.

24. The method of claim 23 wherein said ST receptor ligand is a peptide.

25. The method of claim 24 wherein said ST receptor ligand is a peptide selected from the group consisting of: SEQ ID NO:2, SEQ ID NO:3, SEQ ID NOS:5-54 and fragments and derivatives thereof.

26. The method of claim 25 wherein said ST receptor ligand is a peptide selected from the group consisting of: SEQ ID NO:2, SEQ ID NO:3, SEQ ID NOS:5-54.

27. The method of claim 23 wherein said ST receptor ligand is an antibody, FAb or $F(Ab)_2$.

28. The method of claim 27 wherein said ST receptor ligand is an antibody.

29. The method of claim 23 wherein said active agent is a cytotoxic agent.

30. The method of claim 29 wherein said active agent is selected from the group consisting of methotrexate, doxorubicin, daunorubicin, cytosinarabinoside, etoposide, 5-4 fluorouracil, melphalan, chlorambucil, *cis*-platinum, vindesine, mitomycin, bleomycin, purothionin, macromomycin, 1,4-benzoquinone derivatives, trenimon, ricin, ricin A chain, *Pseudomonas* exotoxin, diphtheria toxin, *Clostridium perfringens* phospholipase C, bovine pancreatic ribonuclease, pokeweed antiviral protein, abrin, abrin A chain, cobra venom factor, gelonin, saporin, modeccin, viscumin, volkensin, nitroimidazole, metronidazole and misonidazole.

31. The method of claim 30 wherein said ST receptor ligand is an antibody, FAb or $F(Ab)_2$.

32. The method of claim 29 wherein said ST receptor ligand is an antibody, FAb or $F(Ab)_2$.

33. The method of claim 23 wherein said ST receptor ligand is a peptide and said active agent is a cytotoxic agent.

34. The method of claim 33 wherein said ST receptor ligand is a peptide selected from the group consisting of: SEQ ID NO:2, SEQ ID NO:3, SEQ ID NOS:5-54 and fragments and derivatives thereof and said active agent is a cytotoxic agent selected from the group consisting of methotrexate, doxorubicin, daunorubicin, cytosinarabinoside, etoposide, 5-4 fluorouracil, melphalan, chlorambucil, *cis*-platinum, vindesine, mitomycin, bleomycin, purothionin, macromomycin, 1,4-benzoquinone derivatives, trenimon, ricin, ricin A chain, *Pseudomonas* exotoxin, diphtheria toxin, *Clostridium perfringens* phospholipase C, bovine pancreatic ribonuclease, pokeweed antiviral protein, abrin, abrin A chain, cobra venom factor, gelonin, saporin, modeccin, viscumin, volkensin, nitroimidazole, metronidazole and misonidazole.

35. The method of claim 34 wherein said ST receptor ligand is a peptide selected from the group consisting of: SEQ ID NO:2, SEQ ID NO:3, SEQ ID NOS:5-54.

36. The method of claim 23 wherein said pharmaceutical composition is administered intravenously.

Sub C5

37. A pharmaceutical composition that comprises:

a) an ST receptor ligand;

b) an active agent, wherein the active agent causes cell death; and

c) a pharmaceutically acceptable carrier or diluent.

38. The pharmaceutical composition of claim 37 wherein said ST receptor ligand is a peptide.

39. The pharmaceutical composition of claim 38 wherein said ST receptor ligand is a peptide selected from the group consisting of: SEQ ID NO:2, SEQ ID NO:3, SEQ ID NOS:5-54 and fragments and derivatives thereof.

40. The pharmaceutical composition of claim 39 wherein said ST receptor ligand is a peptide selected from the group consisting of: SEQ ID NO:2, SEQ ID NO:3, SEQ ID NOS:5-54.

41. The pharmaceutical composition of claim 37 wherein said ST receptor ligand is an antibody, FAb or $F(Ab)_2$.

42. The pharmaceutical composition of claim 41 wherein said ST receptor ligand is an antibody.

43. The pharmaceutical composition of claim 37 wherein said active agent is a cytotoxic agent.

44. The pharmaceutical composition of claim 43 wherein said active agent is selected from the group consisting of methotrexate, doxorubicin, daunorubicin, cytosinarabinoside, etoposide, 5-4 fluorouracil, melphalan, chlorambucil, *cis*-platinum, vindesine, mitomycin, bleomycin, purothionin, macromomycin, 1,4-benzoquinone derivatives, trenimon, ricin, ricin A chain, *Pseudomonas* exotoxin, diphtheria toxin, *Clostridium perfringens* phospholipase C, bovine pancreatic ribonuclease, pokeweed antiviral protein, abrin, abrin A chain, cobra venom factor, gelonin, saporin, modeccin, viscumin, volkensin, nitroimidazole, metronidazole and misonidazole.

45. The pharmaceutical composition of claim 44 wherein said ST receptor ligand is an antibody, FAb or $F(Ab)_2$.

46. The pharmaceutical composition of claim 43 wherein said ST receptor ligand is an antibody, FAb or $F(Ab)_2$.

47. The pharmaceutical composition of claim 37 wherein said ST receptor ligand is a peptide and said active agent is a cytotoxic agent.

Sub C5

48. The pharmaceutical composition of claim 47 wherein said ST receptor ligand is a peptide selected from the group consisting of: SEQ ID NO:2, SEQ ID NO:3, SEQ ID NOS:5-54 and fragments and derivatives thereof and said active agent is a cytotoxic agent selected from the group consisting of methotrexate, doxorubicin, daunorubicin, cytosinarabinoside, etoposide, 5-4 fluorouracil, melphalan, chlorambucil, *cis*-platinum, vindesine, mitomycin, bleomycin, purothionin, macromomycin, 1,4-benzoquinone derivatives, trenimon, ricin, ricin A chain, *Pseudomonas* exotoxin, diphtheria toxin, *Clostridium perfringens* phospholipase C, bovine pancreatic ribonuclease, pokeweed antiviral protein, abrin, abrin A chain, cobra venom factor, gelonin, saporin, modeccin, viscumin, volkensin, nitroimidazole, metronidazole and misonidazole.

49. The pharmaceutical composition of claim 48 wherein said ST receptor ligand is a peptide selected from the group consisting of: SEQ ID NO:2, SEQ ID NO:3, SEQ ID NOS:5-54.

ADD C5